Live Feeds
● LIVE Updated 1h ago · 11 sources tracked

Novartis strikes up to $7.8 billion mRNA deal with China's Abogen

Novartis has entered a licensing agreement with Chinese startup Abogen Biosciences valued at up to $7.8 billion. The deal centers on an mRNA-encoded in vivo autoimmune T-cell engager. Under the terms, Novartis will license the drug candidate and secure options for additional future therapies from the company. This agreement reflects a broader trend of major pharmaceutical firms increasing their investment and partnership activity within the Chinese biotech market.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (11)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Novartis signed a deal with China's Abogen valued at up to $7.8 billion.
  • ✓ The agreement involves licensing an mRNA-encoded T-cell engager.
  • ✓ The drug candidate is an in vivo autoimmune T-cell engager.
🛡️ Source Corroboration: 11 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Novartis signed a licensing deal for an mRNA-encoded T-cell engager from Abogen Biosciences.

Live updates

  1. Novartis signs up to $7.8 billion mRNA deal with China's Abogen

    Novartis has entered a licensing agreement with Chinese startup Abogen Biosciences valued at up to $7.8 billion. The deal centers on an mRNA-encoded in vivo autoimmune T-cell engager. Under the terms, Novartis will license the drug candidate and secure options for additional future therapies from the company. This agreement reflects a broader trend of major pharmaceutical firms increasing their investment and partnership activity within the Chinese biotech market.

    Why it matters

    The partnership focuses on mRNA technology applied to autoimmune treatments. This move aligns with a wider strategic push by global pharmaceutical companies to acquire innovative assets from China.

    What is confirmed

    • Novartis signed a deal with China's Abogen valued at up to $7.8 billion.
    • The agreement involves licensing an mRNA-encoded T-cell engager.
    • The drug candidate is an in vivo autoimmune T-cell engager.

    What to watch next

    • Clinical trial results for the mRNA-encoded T-cell engager
    • Novartis exercising options for additional Abogen therapies
    Sources used for this update (13)
    1. WSJ — Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal
    2. Reuters — Novartis strikes up to $7.8 billion mRNA deal with China's Abogen
    3. CNBC — Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion
    4. fiercebiotech.com — Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
    5. axios.com — Novartis signs $7.8 billion drug deal with Chinese startup
    6. BioSpace — Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
    7. www.devdiscourse.com — Reuters Health News Summary | International
    8. www.globalbankingandfinance.com — IG Group Cuts 2026 Revenue Outlook on Weaker OTC Trading
    9. www.globalbankingandfinance.com — Novartis Signs $7.8B mRNA Licensing Deal With China’s Abogen
    10. www.gdnonline.com — Health: Novartis strikes up to $7.8 billion mRNA deal with China's Abogen
    11. www.marketscreener.com — Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal -- Update | MarketScreener
    12. www.marketscreener.com — Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal | MarketScreener
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community